JP2021513540A5 - - Google Patents
Info
- Publication number
- JP2021513540A5 JP2021513540A5 JP2020542952A JP2020542952A JP2021513540A5 JP 2021513540 A5 JP2021513540 A5 JP 2021513540A5 JP 2020542952 A JP2020542952 A JP 2020542952A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2021513540 A5 JP2021513540 A5 JP 2021513540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000161A JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US62/630,038 | 2018-02-13 | ||
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US62/732,828 | 2018-09-18 | ||
| US201862740741P | 2018-10-03 | 2018-10-03 | |
| US62/740,741 | 2018-10-03 | ||
| PCT/US2019/017188 WO2019160755A1 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000161A Division JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513540A JP2021513540A (ja) | 2021-05-27 |
| JP2021513540A5 true JP2021513540A5 (enExample) | 2022-09-08 |
Family
ID=67620098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542952A Pending JP2021513540A (ja) | 2018-02-13 | 2019-02-08 | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| JP2024000161A Withdrawn JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000161A Withdrawn JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047409A1 (enExample) |
| EP (1) | EP3752193A4 (enExample) |
| JP (2) | JP2021513540A (enExample) |
| KR (1) | KR20200119845A (enExample) |
| CN (2) | CN111727056A (enExample) |
| AU (2) | AU2019222517A1 (enExample) |
| BR (1) | BR112020015915A8 (enExample) |
| CA (1) | CA3090996A1 (enExample) |
| MA (1) | MA51844A (enExample) |
| MX (1) | MX2020008446A (enExample) |
| WO (1) | WO2019160755A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2020185722A2 (en) * | 2019-03-13 | 2020-09-17 | Merck Sharp & Dohme Corp. | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| US20230118596A1 (en) * | 2020-03-05 | 2023-04-20 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof |
| EP4114863A4 (en) * | 2020-03-05 | 2024-04-24 | Merck Sharp & Dohme LLC | METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY |
| WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
| TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| IL310201A (en) * | 2021-07-19 | 2024-03-01 | Regeneron Pharma | Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment |
| JP2024540152A (ja) * | 2021-10-29 | 2024-10-31 | オンコシーフォー、インク． | 抗ｃｔｌａ－４抗体投与レジメン |
| CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| EP4583981A2 (en) * | 2022-09-09 | 2025-07-16 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| CN118767127A (zh) * | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| CN121816195A (zh) * | 2023-08-21 | 2026-04-07 | 艾吉纳斯公司 | 使用ctla-4抑制剂和pd-1抑制剂的组合治疗结直肠癌的方法 |
| TW202511295A (zh) * | 2023-08-31 | 2025-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) * | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| JP2018515474A (ja) * | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| EP3322731B1 (en) * | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
| US20180222989A1 (en) * | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| US20180230431A1 (en) * | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US10358496B2 (en) * | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| ES2954139T3 (es) * | 2016-06-02 | 2023-11-20 | Bristol Myers Squibb Co | Bloqueo de PD-1 con nivolumab en el linfoma de Hodgkin refractario |
| CN109476753A (zh) * | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗肿瘤的方法的抗-pd-1抗体 |
| JP2019517512A (ja) * | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
-
2019
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja active Pending
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 CA CA3090996A patent/CA3090996A1/en active Pending
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt unknown
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/en not_active Ceased
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
- 2019-02-08 CN CN202510115562.9A patent/CN119792515A/zh active Pending
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko not_active Withdrawn
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/en active Pending
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja not_active Withdrawn